• Users Online: 683
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2021  |  Volume : 22  |  Issue : 2  |  Page : 149-156

Liver fibrosis-4 score predicts mortality in critically ill patients with coronavirus disease 2019


1 Department of Anesthesia and Intensive Care, Faculty of Medicine, Tanta University, Tanta, Egypt; Department of Intensive Care, Security Forces Hospital, Riyadh, KSA
2 Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland
3 Department of Statistics, Federal University of Parana, Curitiba, Brazil
4 Department of Neuroscience, Biomedicine and Movement, Section of Clinical Biochemistry, University of Verona, Verona, Italy
5 Department of Intensive Care, Security Forces Hospital, Riyadh, KSA
6 Drug and Poison Information Center, Security Forces Hospital, Riyadh, KSA
7 Department of Rheumatology, Security Forces Hospital, Riyadh, KSA
8 Cardiac Intensive Care Unit, Cincinnati Children's Hospital Medical Center, The Heart Institute, Cincinnati, Ohio, USA

Correspondence Address:
Dr. Mohammed Fawzi Abosamak
Department of Anesthesia and Intensive Care, Faculty of Medicine, Tanta University, Tanta, Post Code 31511

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/TheIAForum.TheIAForum_49_21

Rights and Permissions

Background: Emerging evidence suggests that liver dysfunction in the course of coronavirus disease 2019 (COVID-19) illness is a critical prognostic factor for mortality in COVID-19 patients, and the Fibrosis-4 (FIB-4) score, developed to reflect level of hepatic fibrosis, has been associated with adverse outcomes in hospitalized COVID-19 patients. This study aimed to investigate intensive care unit (ICU) admitted patients, a high-risk subpopulation, research on which is lacking. Materials and Methods: This retrospective cohort study examined FIB-4 scores and clinical endpoints including death, acute cardiac injury (ACI), acute kidney injury, and need for mechanical ventilation in critically ill COVID-19 patients, without prior hepatic disease, throughout ICU stay. Results: Of 60 patients enrolled, 35% had ICU admission FIB-4 >2.67. Among nonsurvivors, FIB-4 was significantly higher at admission (median 3.19 vs. 1.44; P < 0.001) and only a minority normalized <1.45 (36.0%). Each one-unit increment in admission FIB-4 was associated with 67.4% increased odds of death (95% confidence interval [CI], 9.8%–162.6%; P = 0.017). FIB-4 >2.67 was associated with a median survival time of 18 days from ICU admission versus 40 days with FIB-4 <2.67 (P = 0.016). Admission FIB-4 was also higher in patients developing ACI (median 4.99 vs. 1.76; P < 0.001). FIB-4 correlated with age (r = 0.449; P < 0.001), and aspartate transaminase with alanine transaminase (r = 0.674; P < 0.001) and lactate dehydrogenase (r = 0.618; P < 0.001). Conclusion: High ICU admission FIB-4 is associated with mortality in critically ill COVID-19 patients, with failure to normalize at time of death, however, the high score is likely a result of generalized cytotoxicity rather than advanced hepatic fibrosis.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed454    
    Printed8    
    Emailed0    
    PDF Downloaded46    
    Comments [Add]    

Recommend this journal